{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04254978","nct_id":"NCT04254978","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04254978. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Bomedemstat administered daily for 169 consecutive days","label":"Bomedemstat","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-03-23","type":"ACTUAL"},"conditions":["Essential Thrombocythemia"],"enrollment":{"count":73,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Bomedemstat","otherNames":["IMG-7289","MK-3543"],"type":"DRUG"}],"last_update":"2026-05-04","lead_sponsor":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","official_title":"A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients With Essential Thrombocythemia","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-03-23","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","timeFrame":"Up to approximately 30 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an AE","timeFrame":"Up to approximately 28 months"},{"measure":"Percentage of Participants With Platelet Count ≤400 k/μL at Day 169","timeFrame":"Up to day 169"}],"references":[{"citation":"Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr. Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Adv. 2026 May 26;10(10):3494-3504. doi: 10.1182/bloodadvances.2025017575.","pmid":"41758981","type":"RESULT"}],"start_date":{"date":"2020-09-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)","url":"https://clinicaltrials.gov/study/NCT04254978"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04254978"}